Moderna
Quarterly and annual revenue from company filings.
Business lines and operating measures.
Reported quarterly COVID revenue. Quarterly figures · USD
| Period ended | USD | Report |
|---|---|---|
| Jun 30, 2026From Apr 1, 2026 | 91,000,000 | Filed Jul 31, 2026 |
| Mar 31, 2026From Jan 1, 2026 | 345,000,000 | Filed May 1, 2026 |
| Jun 30, 2025From Apr 1, 2025 | 114,000,000 | Filed Jul 31, 2026 |
| Mar 31, 2025From Jan 1, 2025 | 84,000,000 | Filed May 1, 2026 |
Reported quarterly RSV revenue. Quarterly figures · USD
| Period ended | USD | Report |
|---|---|---|
| Jun 30, 2026From Apr 1, 2026 | 3,000,000 | Filed Jul 31, 2026 |
| Mar 31, 2026From Jan 1, 2026 | 7,000,000 | Filed May 1, 2026 |
| Jun 30, 2025From Apr 1, 2025 | 0 | Filed Jul 31, 2026 |
| Mar 31, 2025From Jan 1, 2025 | 2,000,000 | Filed May 1, 2026 |
Reported quarterly Stand-ready manufacturing revenue. Quarterly figures · USD
| Period ended | USD | Report |
|---|---|---|
| Jun 30, 2026From Apr 1, 2026 | 31,000,000 | Filed Jul 31, 2026 |
| Mar 31, 2026From Jan 1, 2026 | 32,000,000 | Filed May 1, 2026 |
| Jun 30, 2025From Apr 1, 2025 | 17,000,000 | Filed Jul 31, 2026 |
| Mar 31, 2025From Jan 1, 2025 | 12,000,000 | Filed May 1, 2026 |
Independent series; they may overlap and do not form an additive breakdown.
Recent Progress and Upcoming Late-Stage Pipeline Milestones Infectious disease vaccines: •Seasonal flu + COVID vaccine: Moderna has received European Commission marketing authorization for mCOMBRIAX in the EU and its mRNA-1083 regulatory filings are under review in Japan, Canada and Australia.
Oncology therapeutics: •Intismeran autogene: The Company is advancing mRNA-4157 in collaboration with Merck, with nine total Phase 2 and Phase 3 clinical trials underway across multiple tumor types including melanoma, non-small cell lung cancer (NSCLC), bladder cancer and renal cell carcinoma.
| Fiscal quarter | Ended | Total revenueUSD millions |
|---|---|---|
| FY 2026 Q2 | Jun 30, 2026 | 145, −62.7% versus FY 2026 Q1 |
| FY 2026 Q1 | Mar 31, 2026 | 389, −42.6% versus FY 2025 Q4 |
| FY 2025 Q4 | Dec 31, 2025 | 678, −33.3% versus FY 2025 Q3 |
| FY 2025 Q3 | Sep 30, 2025 | 1,016, +615.5% versus FY 2025 Q2 |
| FY 2025 Q2 | Jun 30, 2025 | 142, +31.5% versus FY 2025 Q1 |
| FY 2025 Q1 | Mar 31, 2025 | 108, −88.8% versus FY 2024 Q4 |
| FY 2024 Q4 | Dec 31, 2024 | 966, −48.1% versus FY 2024 Q3 |
| FY 2024 Q3 | Sep 30, 2024 | 1,862, +672.6% versus FY 2024 Q2 |
| FY 2024 Q2 | Jun 30, 2024 | 241, +44.3% versus FY 2024 Q1 |
| FY 2024 Q1 | Mar 31, 2024 | 167, −94.1% versus FY 2023 Q4 |
| FY 2023 Q4 | Dec 31, 2023 | 2,811, +53.5% versus FY 2023 Q3 |
| FY 2023 Q3 | Sep 30, 2023 | 1,831, +432.3% versus FY 2023 Q2 |
| FY 2023 Q2 | Jun 30, 2023 | 344, −81.5% versus FY 2023 Q1 |
| FY 2023 Q1 | Mar 31, 2023 | 1,862, −63.4% versus FY 2022 Q4 |
| FY 2022 Q4 | Dec 31, 2022 | 5,084, +51.1% versus FY 2022 Q3 |
| FY 2022 Q3 | Sep 30, 2022 | 3,364, −29.2% versus FY 2022 Q2 |
| FY 2022 Q2 | Jun 30, 2022 | 4,749, −21.7% versus FY 2022 Q1 |
| FY 2022 Q1 | Mar 31, 2022 | 6,066, −15.9% versus FY 2021 Q4 |
| FY 2021 Q4 | Dec 31, 2021 | 7,211, +45.1% versus FY 2021 Q3 |
| FY 2021 Q3 | Sep 30, 2021 | 4,969, +14.1% versus FY 2021 Q2 |
| FY 2021 Q2 | Jun 30, 2021 | 4,354, +124.8% versus FY 2021 Q1 |
| FY 2021 Q1 | Mar 31, 2021 | 1,937, +239.4% versus FY 2020 Q4 |
| FY 2020 Q4 | Dec 31, 2020 | 570.745, +261.4% versus FY 2020 Q3 |
| FY 2020 Q3 | Sep 30, 2020 | 157.91, +138.0% versus FY 2020 Q2 |
| FY 2020 Q2 | Jun 30, 2020 | 66.351, +690.9% versus FY 2020 Q1 |
| FY 2020 Q1 | Mar 31, 2020 | 8.389, −40.3% versus FY 2019 Q4 |
| FY 2019 Q4 | Dec 31, 2019 | 14.055, −17.5% versus FY 2019 Q3 |
| FY 2019 Q3 | Sep 30, 2019 | 17.046, +30.3% versus FY 2019 Q2 |
| FY 2019 Q2 | Jun 30, 2019 | 13.083, −18.4% versus FY 2019 Q1 |
| FY 2019 Q1 | Mar 31, 2019 | 16.025, Change unavailable versus FY 2018 Q4 |
Figures from official company filings and financial reports, in the reported currency. FY identifies the fiscal year; the end date identifies the calendar period. Last checked Oct 19, 2026.
Annual values come from annual filings. Historical quarters retain their reporting basis; rounding and reclassifications can make their sum differ from the annual figure. YTD sums the available fiscal quarters and compares the same quarters of the previous fiscal year.
Missing values are shown as unavailable. Fourth quarters use reported values where available, otherwise the annual amount less the matching nine-month amount.